KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $12.2 million.

  • Halozyme Therapeutics' Share-based Compensation fell 332.33% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.5 million, marking a year-over-year increase of 1170.8%. This contributed to the annual value of $43.4 million for FY2024, which is 1847.35% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Share-based Compensation of $12.2 million as of Q3 2025, which was down 332.33% from $12.2 million recorded in Q2 2025.
  • Halozyme Therapeutics' Share-based Compensation's 5-year high stood at $12.6 million during Q3 2024, with a 5-year trough of $4.7 million in Q1 2022.
  • Its 5-year average for Share-based Compensation is $8.4 million, with a median of $9.4 million in 2023.
  • As far as peak fluctuations go, Halozyme Therapeutics' Share-based Compensation crashed by 367.66% in 2022, and later soared by 7075.42% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Share-based Compensation stood at $5.1 million in 2021, then skyrocketed by 40.91% to $7.2 million in 2022, then surged by 33.79% to $9.7 million in 2023, then increased by 18.61% to $11.5 million in 2024, then grew by 6.09% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, $12.2 million for Q2 2025, and $10.7 million during Q1 2025.